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Background: Multiple Sclerosis (MS) is a multi-factorial disease, where a single biomarker unlikely can provide
comprehensive information. Moreover, due to the non-linearity of biomarkers, traditional statistic is both unsuitable
and underpowered to dissect their relationship. Patients affected with primary (PP=14), secondary (SP=33), benign
(BB=26), relapsing-remitting (RR=30) MS, and 42 sex and age matched healthy controls were studied. We performed
a depth immune-phenotypic and functional analysis of peripheral blood mononuclear cell (PBMCs) by flow-
cytometry. Semantic connectivity maps (AutoCM) were applied to find the natural associations among
immunological markers. AutoCM is a special kind of Artificial Neural Network able to find consistent trends and
associations among variables. The matrix of connections, visualized through minimum spanning tree, keeps non
linear associations among variables and captures connection schemes among clusters.
Results: Complex immunological relationships were shown to be related to different disease courses. Low CD4IL25+
cells level was strongly related (link strength, ls=0.81) to SP MS. This phenotype was also associated to high CD4ROR+
cells levels (ls=0.56). BB MS was related to high CD4+IL13 cell levels (ls=0.90), as well as to high CD14+IL6 cells
percentage (ls=0.80). RR MS was strongly (ls=0.87) related to CD4+IL25 high cell levels, as well indirectly to high
percentages of CD4+IL13 cells. In this latter strong (ls=0.92) association could be confirmed the induction activity of
the former cells (CD4+IL25) on the latter (CD4+IL13). Another interesting topographic data was the isolation of Th9
cells (CD4IL9) from the main part of the immunological network related to MS, suggesting a possible secondary role of
this new described cell phenotype in MS disease.
Conclusions: This novel application of non-linear mathematical techniques suggests peculiar immunological
signatures for different MS phenotypes. Notably, the immune-network displayed by this new method, rather than a
single marker, might be viewed as the right target of immunotherapy. Furthermore, this new statistical technique
could be also employed to increase the knowledge of other age-related multifactorial disease in which complex
immunological networks play a substantial role.
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Multiple Sclerosis (MS) is an autoreactive Tcell–driven
CNS disease representing the most common cause of non-
traumatic disability for the young adult. Different clinical
phenotypes can be recognized in this disease: the most
common clinical phenotype of MS is the relapsing-
remitting (RR) form, which is characterized by an acute
onset of symptoms and signs suggestive of neurological
dysfunction, followed by complete or partial recovery. The
long-term prognosis of RR is usually unfavorable, since
patients enter the so-called secondary progressive (SP)
phase of the disease and accumulate irreversible neuro-
logical disability. Approximately 50% of the patients with
RR will have a transition to SP by 15 years after disease
onset in the absence of any treatment [1]. A different dis-
ease pattern, primary progressive (PP) MS, is seen in
patients showing a progressive course from the onset; an
even rarer form of disease is benign (BB) MS. In this case
absent or minimal neurological impairment are present
many years after the onset manifestation. Notably, whereas
RR MS appears to be largely driven by inflammatory pro-
cesses, neurodegeneration plays an important role in the
chronic brain and spinal cord injury in patients with PP
MS and SP MS. Unfortunately, in spite of the new imaging
biomarkers discovered, the state and course of the disease
remains rather unpredictable. Since long time ago several
studies [2,3] tried to finger out whether peculiar immuno-
logical signatures could be associated with different courses
of MS. Literature data indeed suggest that certain im-
munological relevant markers could identify specific dis-
ease state and disease activity in MS patients [4]. Moreover
findings in humans are corroborated by results from ex-
perimental autoimmune encephalomyelitis (EAE), a well-
established animal model of MS, where a specific pattern
of lymphocyte infiltration and cytokine secretion along
with the different phases of the disease has been described
[5]. Careful analysis of the alterations in immune processes
should further advance knowledge of the pathogenic
mechanisms of this disease, and might have predictive
value toward disease evolution.
Unfortunately, the overall immunological results of lit-
erature are sometimes conflicting and often insufficient to
disclose the effective relationship among studied variables.
Although differences between trial designs, patients’ popu-
lation, immunological markers, and technical methodolo-
gies can explain the most of this inconsistency, statistical
analyses might be an important factor to be considered.
Thus, traditional statistical algorithms are both unsuitable
and underpowered to dissect the relationship between
high number of markers due to the non-linearity and
complexity of the immunological network; a fuzzy cluster-
ing approach based on evolutionary programming (PST)
and Semantic connectivity map (AutoCM) could find the
natural associations among immunological markers.This new artificial adaptive system is able to define the
strength of the associations of each variable with all the
others and to visually show the map of the main connec-
tions of the variables and the basic semantic of their en-
semble. The matrix of connections, visualized through
minimum spanning tree, by AutoCM, keeps non linear
associations among variables and captures connection
schemes among clusters. These artificial adaptive sys-
tems were previously applied to clinical dataset of Alz-
heimer patients [6] where they successfully disclosed
previously unknown connections among the large body
of factors related to this multifactorial disease.
In this pilot study we investigated immunological mar-
kers' network, using AutoCM in 103 MS patients and 42
healthy controls (HC). The same clinical and immuno-
logical dataset was previously studied with traditional
statistical analyses [7].
The aim of this study was to verify these data with a
completely different statistical technique, and to investigate
whether this revolutionary mathematical approach can in-
crease the intelligibility of the immunological connections.
Results
The main relationships between immunological markers
and MS clinical phenotypes emerging from the AutoCM
analyses are shown in Figure 1. Results clearly indicated
that the progressive forms (PP and SP MS) of the disease
can be visually separated from the other clinical pheno-
types (RR and BB). Thus, the progressive forms of MS are
associated with different immunological markers compared
to RR MS and BB MS. By means of AutoCM, it is possible
to obtain not only the direction of the association as pro-
vided by standard statistical analyses, but importantly also
the strength of this association. A reduced percentage of
CD4/IL25+ cells was strongly (ls=0.81) related to second-
ary progressive MS, this phenotype being also (ls=0.56)
associated to increased amounts of CD4/ROR+cells. On
the opposite part of the graph, benign phenotypes (BB MS)
were clearly related to higher quantities of CD4+/IL13 and
CD14+/IL6 cells (ls=0.80). This relationship depicts a com-
parable impact of anti-inflammatory (CD4+IL13 cells) fac-
tors and of inflammatory markers (CD14+IL6 cells) in the
shaping of this favorable clinical course. Interestingly, the
RR MS form was directly associated with CD4+/IL25 cells
(ls=0.87), whereas an indirect association with CD4+/IL13
cells was detected. In turn, CD4+IL25 cells are strongly
(ls=0.92) associated to CD4+IL13 cells, strengthening the
well known induction activity of the former (CD4+/IL25)
on the latter (CD4+/IL13) T lymphocyte populations [8,9].
Another interesting topographic data is the isolation of
Th9 cells (CD4IL9) from the main part of the immuno-
logical network related to MS, suggesting a possible
secondary role of these recently discovered immune cells
in MS.
Figure 1 Semantic connectivity map of the pathway linking immunological markers to different phenotypes of MS. Semantic
connectivity map of variables on study: values ranging from 0 (no association) to 1 (the strongest association) express the strength of association.
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Immunological markers are objective measures with
clinical and scientific relevance. They can be useful in
diagnostic definition/exclusion (e.g., anti acquaporin anti-
bodies to differentiate MS from Neuromyelitis Ottica), to
assess treatment response (e.g., anti IFN neutralizing anti-
bodies in non-responder patients), but also to dissect
pathogenetic mechanisms of disease [10-12]. Due to the
complexity and redundancy of immune system, investigat-
ing the pattern of correlations among immune markers is
a challenging task for traditional statistic. The latter can
provide binary correlation, and show immunological pat-
tern best associated to a clinical phenotype but it is un-
suitable to finger out the non-linear interconnections
among variables. In order to find the natural associations
among immunological markers we applied a fuzzy cluster-
ing approach based on evolutionary programming (PST)
and Semantic connectivity map (AutoCM) to the data of a
wide immunological study, dissecting new pathways of
immunological mechanisms [7]. AutoCM is a special kind
of Artificial Neural Network able to find consistent trends
and associations among variables. The matrix of connec-
tions, visualized through minimum spanning tree, keeps
non linear associations among variables and captures
connection schemes among clusters. The use of this
mathematical approach, as shown by literature [13] should
disclose the complex relationships among markers, other-
wise impossible to be fingered out by traditional analyses.
A global view can suggest how AutoCM can visually sep-
arate the progressive forms of disease (PP and SP) from
RR and BB phenotypes, connecting the last to a network
of different immunological markers. This finding could bethe immunological support of the better prognosis and
less destructive mechanisms associated to RR and BB
compared to SP and PP.
In particular, AutoCM found a strong relationship be-
tween RR and high percentages of IL25-expressing CD4
cells. These lymphocytes are central in down-regulating
the inflammatory potential of TH17 cells, directly or via
IL-13- secreting CD4 cells [8,14]. Thus, it has been sug-
gested that the disease can enter temporary quiescence
phase (remission) by these anti-inflammatory mechan-
isms. Interestingly the AutoCM caught the sense of this
relationship, showing the direct link of RR phenotype to
IL-25 CD4 cells and indirect with IL-13- secreting CD4
cells, confirming preliminary data from literature but
even adding new information. Our previous study
showed that IL-6-expressing CD14+ cells were signifi-
cantly augmented in all the different MS phenotypes.
The differentiation processes of these cells occurring
when they get the target tissue, mainly depends on in-
flammatory or anti-inflammatory milieu they find. Ac-
cordingly, most of these cells find in the inflammmated
CNS the ideal milieu priming their differentiation into
functional myeloid dendritic cells able to support the
proliferation and expansion of TH17 cells [15]. In turn
these latter cells orchestrate the effective inflammatory
damage to myelin and cells. Interestingly, the new find-
ing provided with this analyses suggest that IL-6-
expressing CD14+ cells play a role also in benign course,
but are strictly associated (in the visual map) with IL-13-
expressing CD4 cells. These lymphocytes are endowed
with anti-inflammatory properties [16] and therefore
could turn off the potential detrimental effect of IL-6-
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clarity and strength of the relationship between IL-6-
secreting CD14+ cells and IL-13- secreting CD4 cells
definitely comes out better by AutoCM analyses. Con-
sidering the upper part of the graph, the most striking
element is the central hub represented by low percent-
age of IL-25/CD4 cells. These cells, as aforementioned,
represent one of the most important ways to regulate an
inflammatory response [8]. Low levels of IL-25 CD4 cells
could be associated to a predisposing condition to in-
flammation that would be further enhanced by the co-
presence of inflammatory cells (e.g., CD4+ROR+cells).
The co-existence of low IL-25 CD4 and high CD4+
ROR+cells is shown by AutoCM as the signature of SP
phenotype. These data suggest that the defect of a
counter-regulative (anti-inflammatory) mechanism could
be a possible explanation for the particularly aggressive
course of SP MS. Figure 1 shows how strong is also the
link between low IL-25 CD4 and PP as well as between
IL-25CD4 and HC . However it’s worth to note that by
AutoCm analyses PP is not shown to be associated with
high percentages of CD4+/ROR+ cells as SP is; it is
tempting to speculate that this difference might play a
role in determining the clinical course of these different
phenotypes. Our data are in line with literature that high-
lights the paucity and controversial role of inflammation
present in PP comparing with other MS phenotypes [17].
Notably, low levels of IL-25/CD4 cells were also asso-
ciated to healthy subjects, but again in this group the as-
sociation with high inflammatory subsets (CD4+ROR
+cells) lacks. This data could suggest that a defective
anti-inflammatory response could not be per se a suffi-
cient condition leading to multiple sclerosis. The carrier-
ship of other immunological risk factors (beyond the
focus of our investigation) and/or non-immunogical
(genetic, epigenetic, and environmental) variables can
make this anti-inflammatory impairment the trigger for
the disease. Interestingly, CD4+IL9 secreting cells (Th9)
were clearly “topographically excluded”. This newly
described functional immunological phenotype has been
suggested to be involved in the pathogenesis of auto-
immune diseases [18,19]. Moreover these cells seem to
be the trigger of the inflammatory response driven by
Th17 during MS [20]. However our previous study [7]
failed to detect a clear difference in IL-9-secreting cells
between any clinical MS phenotype and HC. AutoCM
strengthen this finding with a different analysis indicating
the contemporary association of Th9 cells to the 3 main
immune CD4+ T lymphocytes phenotypes: Th2
(CD4GATA+), Th1 (CD4TBET) and Th17 (CD4IL22). In
conclusion, we presented a new mathematical algorithm
to dissect a complex network of variables. The AutoCM
system reshapes the distances among immunological
variables elsewhere studied by standard approach.Conclusion
In conclusion AutoCM clearly show PP and SP strongly
associated to “lowCD4IL25”, conversely BB appear
related to both “high CD14 IL13” and “high CD4IL6”
immunological signature. Being MS a multifactorial dis-
order, several other biological variables (genetic, epigen-
etic, transcriptomics. . .) rely on the clinical differences
of these opposite phenotypes. Notwithstanding the need
of other reliable biological markers, our findings shed
further light on the meaning of the immunological mar-
kers associated to different disease courses”
The superiority of AutoCM method compared to those
obtained with Euclidean or other linear-correlation-dis-
tance-matrix-based analyses is evidenced by the global in-
formation it provides. Not only the reciprocal binary
connection among biological and clinical variables, but
the totality of these connections and the strength of the
entire immunological network can be disclosed by this
new revolutionary method. These data sound to suggest
that future studies based on this new mathematical ap-
proach could better define also the relationship between
the inflammatory component and neurodegeneration fac-
tors involved in MS. Moreover, AutoCM could be a useful
tool to finger out complex networks underpinning age-
related multifactorial diseases.
Increasing knowledge of so far unveiled relationships
of factors involved in these diseases could pave the way
for more specific drugs.
Methods
We performed a depth immune-phenotypic and func-
tional analysis of peripheral blood mononuclear cell
(PBMCs) by flow cytometry on 103 MS patients and
42 HC. Studied population consisted of 103 MS
patients with relapsing remitting (RR, n= 30), benign
(BB, n=26), primary (PP, n=14), or secondary progres-
sive (SP, n=33) MS diagnosed according international
consensus criteria [21].
Clinical history and drug assumption were recorded
and neurological examination was performed, including
the Expanded Disability Status Scale (EDSS) rating.
Patients were considered affected by BB MS when EDSS
score was ≤ 3.0 and disease duration equal to or longer
than 15 years [22]. Median disease duration was 7 years
(range: 1–29 years); the median Expanded Disability Sta-
tus Scale (EDSS) score was 1.5 (range: 1–6). Demo-
graphic and clinical data are reported in Table 1.
Patients were recruited at Multiple Sclerosis Center Fon-
dazione Don Carlo Gnocchi (Milan) and CAM, Polidiag-
nostic Center (Monza).
All subjects had to be free of relapse or of a confirmed
disease progression in the last 30 days and stopped any
immunosuppressive drugs at least 12 months before en-
rollment; symptomatic drugs (SSRI, Baclofen, Oxibutine)
Table 1 Demographic and clinical data of studied patients and healthy controls
RR BB SP PP HC
N 30 26 33 14 42
Age (range) 40 (20–59) 45 (36–61) 49 (32–67) 50 (37–64) 48 (32–62)
F:M 19:11 18:8 21:12 6:8 28:14
Disease duration 7 21 20 12 –
EDSS 1.5 2 6.5 6 –
Relapsing remitting (RR); benign (BB); secondary progressive (SP); and primary progressive (PP) multiple sclerosis patients were selected. A group of 42 sex and
age matched healthy controls (HC) were enrolled in the study as well. F: female, M: male. Average and range of age are reported, EDSS: Expanded disability status
scale. Age values are not significantly different among MS subgroups; EDSS, as expected, is higher in PP and SP subgroups in comparison with RR and BB.
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unstable medical condition (cardiovascular, pulmonary,
hepatic, gastrointestinal, renal, metabolic diseases or ma-
lignancies) were excluded from the study. Following ac-
quisition of informed consent, fasting blood samples were
collected in the morning and immediately analyzed.
Blood sample collection and cell separation
Whole blood was collected in vacutainer tubes containing
ethylenediaminetetraacetic acid (EDTA) (Becton Dickinson
& Co., Rutherford, NJ, USA). Peripheral blood mono-
nuclear cells (PBMC) were separated on lymphocyte separ-
ation medium (Organon Teknika Corp., Durham, NC,
USA) and washed twice in PBS. Viable leukocytes were
determined by ScepterTM Handheld Automated Cell
Counter (Millipore, MA, USA).
Synthesis of the MBP peptides
Thirty-one HLA I restricted and 7 HLA II restricted
promiscuous peptides partially overlapping and spanning
the whole Myelin Basic Protein (MBP) were synthesized
using Fmoc chemistry. Peptides purity, as assayed by
HPLC, was > 70%, and their composition was verified by
mass spectrometry. Lyophilized peptides were dissolved
at 25 mg/ml in DMSO or sterile water to prepare pep-
tide pools (10 mg/ml final concentration).
Stimulation of PBMC for FACS analysis
1 x 106 PBMC were stimulated with non-immunogenic
peptides or with a pool of the MBP peptides (10 mg/ml) +
anti-CD28 mAb (clone 37407.111; R&D Systems, Inc., Min-
neapolis, MN,USA) (1 μg/ml) to facilitate co-stimulation, at
37°C in a humidified 5% CO2 atmosphere for 24 hours.
Fr cytokine analyses, 10 μg/ml Brefeldin A (Sigma-Aldrich,
St. Louis, MO,USA) was added to the cell cultures during
the last 6 h of stimulation to block protein secretion.
Immunofluorescent staining
PBMC were stained with CD4, CD19 and CD14 mAbs
(Beckman Coulter, Brea, CA, USA), washed in PBS and
treated with FIX and PERM (FIX & PERM Cell
Permeabilization kits; eBioscience San Diego, CA, USA),
then fixed for 10 min in fixation medium (100 μl),washed, and suspended in 100μl of permeabilization
medium with mAbs against the following proteins: anti-
RORC/RORγτ, anti-T-bet, anti- GATA3, anti- NFkB,
anti-NFATc1, or with IFN-γ IL-4, IL-6, IL-9, IL-10, IL-
12, IL-13, IL-17, IL-21, IL-22, IL-23, IL-25 and TGF-β-
specific mAb FITC or PE-conjugated for 30 minutes at
4°C in the dark.
Monoclonal Abs
The following mAbs were used in this study: Phycoerythrin-
Cyanin-7 (PC7)- labeled anti-CD4 (clone SFCI12T4D11)
(mouse IgG1), Fluorescein Isothiocyanate (FITC)-or
Phycoerythrin-Cyanin-5 (PC5) labeled anti-CD14 (clone
116), (Beckman-Coulter, Fullerton, CA). The intracellular
molecule detection mAbs used were: anti-human Phyco-
erythrin (PE)-coupled IL-10 (clone JES9D7; mouse IgG1 iso-
type; Caltag Laboratories), anti-human IL-4 FITC (clone
MP4-25D2, rat IgG1k isotope, eBioscience Cornerstone
Court West, San Diego, CA), anti-human IFNγ-PE, anti-
human IL-6- FITC (clone 1936, mouse IgG2B isotope, R&D
Systems Inc., Minneapolis), anti-human IL-9- PE (clone
MH9A4, mouse IgG2B,k isotype, Biolegend, San Diego, CA),
anti-human IL-12- FITC (clone 27537, mouse IgG1 isotype,
R&D), anti-human IL-13 FITC (clone 32007, mouse IgG1i-
sotype, R&D) anti-human IL-17-PC5 (clone BL168, mouse
IgG1k isotype, Biolegend), anti-human IL-21-PE (clone 3A3-
N2, mouse IgG1 isotype, eBioscience), anti-human IL-22-PE
(clone 142928, mouse IgG1 isotype R&D), anti-human IL-
23-PE (clone C11.5, mouse IgG1k isotype, Biolegend), anti-
human IL-25-PE (IL-17E, clone 182203, mouse IgG1isotype,
R&D) anti-mouse/human RORC/RORγτPE (clone AFKJS-9,
rat IgG2a isotype, eBioscience), anti-mouse/human T-bet-
PE (clone 39D, mouse IgG1 isotype, eBioscience), anti-
mouse/human GATA3-PE (clone TWAY, rat IgG2B,k isotype,
eBioscience), anti- human NFkB-FITC (clone C-5, mouse
IgG2a isotype, Santa Cruz Biotechnology, Santa Cruz, CA),
anti- human NFATc1-PE (clone H-10, mouse IgG1 isotype,
Santa Cruz-Biotechnology).
Cytometric analysis
Analyses were performed using a Beckman-Coulter
Cytomics FC-500 flow cytometer equipped with a single
15 mW argon ion laser operating at 488 nm and
Table 2 Variables' transformation
Original variables Variables’ transformation
1 CD4+RORC/γτ+ 1- CD4+RORC/γτ+
2 CD4+IL17A+ 1- CD4+IL17A+
3 CD4+IL22+ 1- CD4+IL22+
4 CD4+TBET+ 1- CD4+TBET+
5 CD4+IL9+ 1- CD4+IL9+
6 CD4+GATA+ 1- CD4+GATA+
7 CD4+IL13+ 1- CD4+IL13+
8 CD4+IL25+ 1- CD4+IL25+
9 CD14+IL6+ 1- CD14+IL6+
10 CD19+IL-6+ 1- CD19+IL-6+
11 CD19+TGFβ 1- CD19+TGFβ
We transformed the 11 immunological variables in 22 input variables and we
made for each of the variable, scaled from 0 to 1, its complement as better
detailed in the text.
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thousands events were acquired and gated on CD4 or
CD14 expression and side scatter properties. Data were
collected using linear amplifiers for forward and side
scatter and logarithmic amplifiers for FL1, FL2, FL4 and
FL5. Samples were first run using isotype control or sin-
gle fluorochrome-stained preparations for color com-
pensation. Rainbow Calibration Particles (Spherotec, Inc.
Lake Forest, IL) were used to standardize results in sam-
ples obtained over time.
Mathematical methods
The analysis performed on this database has the aim of
increasing our understanding of the complex pathway
linking immunological markers to different phenotypes
of MS. This goal has been achieved through a new data
mining method, based on a particular artificial adaptive
system, the Auto Semantic Connectivity Map (AutoCM),
that is able to compute the association strength of each
variable with all the others in any dataset (i.e. in terms
of many-to-many rather than dyadic associations). The
architecture and mathematics of AutoCM is described
elsewhere [13,23].
In non-technical terms, AutoCM is a new data mining
tool based on an Artificial Neural Network developed at
Semeion Research Center [24] that is especially effective
at highlighting any kind of consistent patterns and/or
systematic relationships and hidden trends and associa-
tions among variables. Quite uncommonly, the weights
determined by AutoCM after the training phase, admit a
direct interpretation. Specifically, they are proportional
to the strength of many-to-many associations across all
variables. This allows a further, useful processing: asso-
ciation strengths may be easily visualized by transform-
ing weights into physical distances. Such a 'translation'
proceeds in an intuitive way: couples of variables whose
connection weights are higher get relatively nearer, and
vice versa. By applying a simple mathematical filter
such as the minimum spanning tree to the matrix of
distances, a graph is generated, whose use has been
already tested in the medical field [6,25], and that is
termed connectivity map as detailed by Buscema and
colleagues [13,25]. This representation then allows a
very intuitive visual mapping of the complex web of
connection schemes among variables, and greatly eases
the detection of the variables that play a key role in the
schemes, i.e. that turn out to be “hubs” of the graph.
The system provides also a quantification of the
“strength” of links among variables (nodes of the graph)
by a numerical coefficient (link strength, ls) ranging
from zero to 1.
The value superimposed to the link is proportional to
the strength of the link. The strength of the link (ls) ranges
from 0 (minimum strength) to 1 (maximal strength).The strength of the link can be read as the probability
of transition from any state-variable to anyone else.
The AutoCM matrix of connections preserves non lin-
ear associations among variables, while at the same time
capturing elusive connection schemes among clusters
that are often overlooked by traditional cluster analyses,
and highlighting complex similarities among variables
on various dimensions–role, connectivity, essentiality,
and so on. The AutoCM algorithms used for all the
computations presented in this paper are implemented
only by a Semeion proprietary research software, which
is exclusively available for academic purposes.
The immunological findings obtained by FACS were
translated in absolute natural values, scaled from 1 to
zero, becoming single inputs for AutoCM
We transformed the 11 immunological variables in 22
input variables constructing for each of the variable,
scaled from zero to 1, its complement (Table 2).
Consider for example the variable CD14_IL6. Absolute
natural values range from 0.1 to 60. According to the
transformation, 60 (the highest value) becomes 1 and 0.1
(the lowest value) becomes 0. All other natural values
are scaled in this new range. For instance: the value 25
becomes 0.41; the value 11 becomes 0.18, etc. The pro-
jection of the variable in the map will point out the fuzzy
position of CD14_IL6 according to its high values. In the
complement transformation, by subtracting the scaled
value from 1 (e.g. 11 becomes now 0.82) we allow the sys-
tem to project and point out the fuzzy position of
CD14_IL6 according to its low values. This is important
because in non linear systems, the position of high and
low values of a given variable is not necessarily symmetric.
In this way the projection of the original variables
tended to show high values while the complement trans-
formation tended to show low values of the original vari-
ables. In the map we have named these two different
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cessary to make possible a proportional comparison
among all the variables and understand the existing links
of each variable when the values tend to be high or low.
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